New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed Notified -
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed Notified -
Zoom unveils AI Companion 3.0 at Zoomtopia 2025, enhancing agentic AI across the Zoom platform Notified -
Mavenir’s AI-Driven Fraud Defense Solutions Win FutureNet Asia Award for Customer Experience Innovation Notified -
Schneider Electric Announces New Reference Designs, Featuring Integrated Power Management and Liquid Cooling Controls, Supporting NVIDIA Mission Control and NVIDIA GB300 NVL72 Notified -
